MovDisordV3, PascalFrancis, Corpus, bibRecord, 001A29

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

Identifieur interne : 001A29 ( PascalFrancis/Corpus ); précédent : 001A28; suivant : 001A30

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

Auteurs : Ji-Youn Kim ; EUN JOO CHUNG ; SEUNG WOO PARK ; WON YONG LEE

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0435109

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Cardiopathie valvulaire, Parkinson maladie, Traitement, Ergot dérivé, Stimulant dopaminergique, Bromocriptine, Pergolide.

English descriptors

KwdEn :
- Bromocriptine, Cardiac valvular disease, Dopamine agonist, Ergot derivatives, Nervous system diseases, Parkinson disease, Pergolide, Treatment.

Abstract

Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age-matched controls based on the two-dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists`
A11	`01`	`1`		`@1 KIM (Ji-Youn)`
A11	`02`	`1`		`@1 EUN JOO CHUNG`
A11	`03`	`1`		`@1 SEUNG WOO PARK`
A11	`04`	`1`		`@1 WON YONG LEE`
A14	`01`			`@1 Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine @2 Seoul @3 KOR @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine @2 Seoul @3 KOR @Z 3 aut.`
A20				`@1 1261-1264`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000142193570400`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 06-0435109`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age-matched controls based on the two-dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Cardiopathie valvulaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Cardiac valvular disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Cardiopatía valvular @5 02`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`05`	`X`	`FRE`	`@0 Ergot dérivé @5 10`
C03	`05`	`X`	`ENG`	`@0 Ergot derivatives @5 10`
C03	`05`	`X`	`SPA`	`@0 Ergot derivado @5 10`
C03	`06`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 11`
C03	`06`	`X`	`ENG`	`@0 Dopamine agonist @5 11`
C03	`06`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 11`
C03	`07`	`X`	`FRE`	`@0 Bromocriptine @2 NK @2 FR @5 12`
C03	`07`	`X`	`ENG`	`@0 Bromocriptine @2 NK @2 FR @5 12`
C03	`07`	`X`	`SPA`	`@0 Bromocriptina @2 NK @2 FR @5 12`
C03	`08`	`X`	`FRE`	`@0 Pergolide @2 NK @2 FR @5 13`
C03	`08`	`X`	`ENG`	`@0 Pergolide @2 NK @2 FR @5 13`
C03	`08`	`X`	`SPA`	`@0 Pergolida @2 NK @2 FR @5 13`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Encéphale pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 289`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0435109 INIST
ET :	Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
AU :	KIM (Ji-Youn); EUN JOO CHUNG; SEUNG WOO PARK; WON YONG LEE
AF :	Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine/Seoul/Corée, République de (1 aut., 2 aut., 4 aut.); Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine/Seoul/Corée, République de (3 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 8; Pp. 1261-1264; Bibl. 17 ref.
LA :	Anglais
EA :	Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age-matched controls based on the two-dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Cardiopathie valvulaire; Parkinson maladie; Traitement; Ergot dérivé; Stimulant dopaminergique; Bromocriptine; Pergolide
FG :	Appareil circulatoire pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Cardiac valvular disease; Parkinson disease; Treatment; Ergot derivatives; Dopamine agonist; Bromocriptine; Pergolide
EG :	Cardiovascular disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Cardiopatía valvular; Parkinson enfermedad; Tratamiento; Ergot derivado; Estimulante dopaminérgico; Bromocriptina; Pergolida
LO :	INIST-20953.354000142193570400
ID :	06-0435109

Links to Exploration step

Pascal:06-0435109

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists</title>
<author><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji-Youn" last="Kim">Ji-Youn Kim</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eun Joo Chung" sort="Eun Joo Chung" uniqKey="Eun Joo Chung" last="Eun Joo Chung">EUN JOO CHUNG</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seung Woo Park" sort="Seung Woo Park" uniqKey="Seung Woo Park" last="Seung Woo Park">SEUNG WOO PARK</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Won Yong Lee" sort="Won Yong Lee" uniqKey="Won Yong Lee" last="Won Yong Lee">WON YONG LEE</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0435109</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0435109 INIST</idno>
<idno type="RBID">Pascal:06-0435109</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists</title>
<author><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji-Youn" last="Kim">Ji-Youn Kim</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eun Joo Chung" sort="Eun Joo Chung" uniqKey="Eun Joo Chung" last="Eun Joo Chung">EUN JOO CHUNG</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seung Woo Park" sort="Seung Woo Park" uniqKey="Seung Woo Park" last="Seung Woo Park">SEUNG WOO PARK</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Won Yong Lee" sort="Won Yong Lee" uniqKey="Won Yong Lee" last="Won Yong Lee">WON YONG LEE</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term>
<term>Cardiac valvular disease</term>
<term>Dopamine agonist</term>
<term>Ergot derivatives</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Pergolide</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Cardiopathie valvulaire</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Ergot dérivé</term>
<term>Stimulant dopaminergique</term>
<term>Bromocriptine</term>
<term>Pergolide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age-matched controls based on the two-dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KIM (Ji-Youn)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>EUN JOO CHUNG</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SEUNG WOO PARK</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WON YONG LEE</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1261-1264</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000142193570400</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0435109</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age-matched controls based on the two-dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cardiopathie valvulaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cardiac valvular disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cardiopatía valvular</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Pergolida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>289</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0435109 INIST</NO>
<ET>Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists</ET>
<AU>KIM (Ji-Youn); EUN JOO CHUNG; SEUNG WOO PARK; WON YONG LEE</AU>
<AF>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine/Seoul/Corée, République de (1 aut., 2 aut., 4 aut.); Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine/Seoul/Corée, République de (3 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 8; Pp. 1261-1264; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age-matched controls based on the two-dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Cardiopathie valvulaire; Parkinson maladie; Traitement; Ergot dérivé; Stimulant dopaminergique; Bromocriptine; Pergolide</FD>
<FG>Appareil circulatoire pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Cardiac valvular disease; Parkinson disease; Treatment; Ergot derivatives; Dopamine agonist; Bromocriptine; Pergolide</ED>
<EG>Cardiovascular disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Cardiopatía valvular; Parkinson enfermedad; Tratamiento; Ergot derivado; Estimulante dopaminérgico; Bromocriptina; Pergolida</SD>
<LO>INIST-20953.354000142193570400</LO>
<ID>06-0435109</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A29 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A29 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0435109
   |texte=   Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri